该患者发病时IPSS-R为MDS处于中危,后合并皮肤溃烂,进展为MDS-EB2,IPSS-R为高危,疾病呈进展状态。现有研究显示,阿扎胞苷联合维奈克拉在初治以及复发/难治高危MDS患者中均表现出良好的疗效[1,2],故该患者入院后拟给予阿扎胞苷联合维奈克...
By comparison, a higher prevalence of MDS-MLD, MDS-EB2, and MDS-RS was found in the French cohort. Armenian patients' cohort generally had poor access to standard MDS treatment and 42.3% of the patients were transfusion dependent. Overall survival, however, did not significantly differ between...
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemi... K Miyazawa,J Nishimaki,K Ohyashiki,... - 《Leukemia》 被引量: 74发表: 2000年 加载更多研究...
clinically secondary AML, and treatment including allogeneic transplantation, patients with World Health Organization-defined AML (n=769) have similar rates of overall survival, event-free survival, and complete remission (CR)/CR with incomplete hematologic recovery as patients with MDS-EB2 (n=202)....
陈宏伟-秦皇岛市第一医院:MDS-EB-1和EB-2时原幼单核我都计数。WHO还说异常中幼粒不是原始细胞等同细胞呢。 沈玉雷老师-美国亨利福特医院:t(8;21) 原始细胞1%也可以诊断。 温凌玉-河南省周口市中心医院:在M2b就是原始细胞等同细胞了。 冷梅-青岛市第八医院:幼单等同于原始细胞,应用于MDS的话,就算认得准,...
Background and aims : intensive chemotherapy (IC) has been used since the early 90's in the treatment of higher risk MDS, yielding 40 to 50% complete response (CR) but prolonged myelosuppression and 10 to 30% early deaths. IC is also recommended before allogeneic (allo) SCT when marrow ...
Background:ENA is a selective inhibitor of IDH2 approved in the US for the treatment of patients with relapsed/refractory IDH2 mutated AML. Little is known on its efficacy in patients with IDH2m myelodysplastic syndromes. Here we report the preliminary results of a Phase 2 study evaluating the...
The standard treatment concept and approach in MDS aims for apoptosis-induction in expanding malignant clones in the hope that this will permit recovery by functionally normal hematopoietic stem cells (HSC). This concept is fundamentally... RZ Mahfouz,MD/PhD,E Rickki,... - Ash Meeting & Exposi...
Seattle data indicate that after accounting for European LeukemiaNet (ELN) 2017 risk, age, performance status, clinically secondary AML, and treatment including allogeneic transplant, patients with WHO-defined AML (n=769) have similar rates of OS, EFS and CR/CRi as patients with MDS-EB2 (n=...
Seattle data indicate that after accounting for European LeukemiaNet (ELN) 2017 risk, age, performance status, clinically secondary AML, and treatment including allogeneic transplant, patients with WHO-defined AML (n=769) have similar rates of OS, EFS and CR/CRi as patients with MDS-EB2 (n=...